North America’s medical devices industry sees a drop of 11.4% in deal activity in Q2 2020

24 July 2020 (Last Updated July 24th, 2020 13:31)

North America’s medical devices industry sees a drop of 11.4% in deal activity in Q2 2020

North America’s medical devices industry saw a drop of 11.4% in overall deal activity during Q2 2020, when compared to the four-quarter average, according to GlobalData’s deals database.

  • Embed this chart

    Embed this chart into your website

    Copy and paste the code below into your website to display the chart.

A total of 240 deals worth $4.72bn were announced for the region during Q2 2020, against the last four-quarter average of 271 deals.

Of all the deal types, venture financing saw most activity in Q2 2020 with 161, representing a 67.1% share for the region.

In second place was M&A with 54 deals, followed by private equity deals with 25 transactions, respectively capturing a 22.5% and 10.4% share of the overall deal activity for the quarter.

In terms of value of deals, venture financing was the leading category in North America’s medical devices industry with $2.48bn, while M&A and private equity deals totalled $1.85bn and $387.52m, respectively.

North America medical devices industry deals in Q2 2020: Top deals

The top five medical devices deals accounted for 48.9% of the overall value during Q2 2020.

The combined value of the top five medical devices deals stood at $2.3bn, against the overall value of $4.72bn recorded for the quarter.

The top five medical devices industry deals of Q2 2020 tracked by GlobalData were:

1) InVitae’s $1.4bn acquisition of ArcherDx

2) The $390m venture financing of Grail by Canada Pension Plan Investment Board, Illumina and Public Sector Pension Investment Board

3) Walmart’s $200m asset transaction with CareZone

4) The $194m venture financing of American Well by Allianz X and Takeda Pharmaceutical

5) Ally Bridge Group, Asahi Kasei Medical, Bain Capital Life Sciences, Endeavour Vision, Longitude Capital Management Co, Quaker Partners Management and Xeraya Capital Sdn’s venture financing of Rapid Micro Biosystems for $120m.

Verdict deals analysis methodology

This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.

GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.

More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.